Posted on 4/2/19
Berkshire Hathaway Q1 Earnings, Q1 Book Value Estimates
SummaryBerkshire should report a solid Q1, driven by steady performance in its operating businesses.Book value has recovered meaningfully from Q4, primarily driven by Apple and Bank . . .
Posted on 4/2/19
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) . . .
Posted on 4/1/19
Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced . . .
Posted on 4/1/19
Candel Therapeutics Completes $22.5 Million Series C
Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the closing of a $22.5 million Series C Preferred Stock financing led by Northpond Ventures. Participating syndicate members included . . .
Posted on 4/1/19
X4 Pharmaceuticals Provides Business and Clinical Development Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today provided a . . .
Posted on 4/1/19
Novartis to Acquire IFM Tre
IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system,
Posted on 4/1/19
Mogrify Subsidiary Chondrogenix Secures Funding from SBRI Healthcare
Chondrogenix, a wholly owned subsidiary of Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies
Posted on 4/1/19
SpringWorks Therapeutics Completes $125 Million Series B Financing
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer
Posted on 4/1/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
SummaryCELG appears to be about to become a BMY asset, based on end-of-week news flow.The surge in CELG shares and drop in BMY below $48 lead . . .
Posted on 4/1/19
Tufts Health Plan Earns Highest Rating Possible in 2019 Corporate Equality Index
Tufts Health Plan received a perfect score on the 2019 Corporate Equality Index (CEI), the nation's premier benchmarking survey and report on corporate policies and practices . . .
Posted on 3/31/19
ImmuCell Corp. Closes $9 Million Public Offering of Common Stock
PORTLAND, Maine, March 29, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products . . .
Posted on 3/31/19
Chiasma Prices Underwritten Public Offering of $30.0 Million of Common Stock
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and . . .
Posted on 3/31/19
Aileron Therapeutics Announces Pricing of $26M Private Placement
WATERTOWN, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and . . .
Posted on 3/29/19
Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining
The road to FDA approval is littered with failed drug candidates. For every 10 that head into clinical trials with high hopes, one will get to . . .
Posted on 3/29/19
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Biogen's (NASDAQ:BIIB) bid to reshape Alzheimer's disease treatment was delivered a big blow last week when it decided to bail on its once-promising Alzheimer's drug aducanumab. . . .
Posted on 3/29/19
Blueprint Medicines Prices Public Offering of Shares of Common Stock
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten . . .
Posted on 3/28/19
Chiasma Announces Proposed Offering of Common Stock
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and . . .
Posted on 3/28/19
EyePoint Pharmaceuticals Prices Public Offering of Common Stock
WATERTOWN, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today . . .
Posted on 3/28/19
Corbus Pharmaceuticals Provides Management Team Updates
Norwood, MA, March 28, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced several changes to its management team. Mark Tepper, Ph.D., will be . . .
Posted on 3/28/19
Mitsubishi Tanabe Pharma America Announces Collaboration With Massachusetts General Hospital On ALS Biomarker Study
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a collaboration with the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct a study designed . . .
Posted on 3/28/19
Centene's New Hampshire Subsidiary Wins Medicaid Contract
Centene Corporation (NYSE: CNC) announced today its New Hampshire subsidiary, NH Healthy Families, has been selected by the New Hampshire Department of Health & Human Services . . .
Posted on 3/28/19
Hyalex Orthopaedics, Synthetic Cartilage Company, Adds New Funding
Hyalex Orthopaedics, a medical device company advancing new products that feature HYALEX technology, a novel polymer system that is intended to mimic cartilage, today announced it . . .
Posted on 3/28/19
swyMed Partners with Life Image
NEWTON, Mass.--(BUSINESS WIRE)--Life Image, the world's largest global network for sharing clinical and imaging data that is powered by industry leading interoperability standards, and swyMed, a . . .
Posted on 3/28/19
Thermo Fisher Makes Move In Gene Therapy Space To Help Services Business Unit
SummaryThermo Fisher acquires gene therapy contract manufacturing development organization Brammer Bio for $1.7 billion in cash.Brammer Bio has experience in helping pharmaceutical companies in ex vivo . . .
Posted on 3/28/19
ImmuCell Corp. Prices $9.0 Million Public Offering of Common Stock
PORTLAND, Maine, March 27, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products . . .

